Skip to main content

EXPLORANDO EL PAPEL DEL ESTRES REPLICATIVO EN CANCER Y ENVEJECIMIENTO

SAF2011-23753

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Replication stress and cancer: It takes two to tango

  • Lecona, Emilio
  • Fernández-Capetillo, Óscar
Problems arising during DNA replication require the activation of the ATR–CHK1 pathway to ensure the stabilization and repair of the forks, and to prevent the entry into mitosis with unreplicated genomes. Whereas the pathway is essential at the cellular level, limiting its activity is particularly detrimental for some cancer cells. Here we review the links between replication stress (RS) and cancer, which provide a rationale for the use of ATR and Chk1 inhibitors in chemotherapy. First, we describe how the activation of oncogene-induced RS promotes genome rearrangements and chromosome instability, both of which could potentially fuel carcinogenesis. Next, we review the various pathways that contribute to the suppression of RS, and how mutations in these components lead to increased cancer incidence and/or accelerated ageing. Finally, we summarize the evidence showing that tumors with high levels of RS are dependent on a proficient RS-response, and therefore vulnerable to ATR or Chk1 inhibitors., Work in the OF laboratory is supported by the Spanish Ministry of Science (SAF2011-23753), Association for International Cancer Research (12-0229), Fundació LaMarató de TV3 (33/C (2013)), Howard Hughes Medical Institute and the European Research Council (ERC-210520)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development

  • Specks, Julia
  • Lecona, Emilio
  • López-Contreras, Andrés J.
  • Fernández-Capetillo, Óscar
The ribonucleotide reductase (RNR) complex, composed of a catalytic subunit (RRM1) and a regulatory subunit (RRM2), is thought to be a rate-limiting enzymatic complex for the production of nucleotides. In humans, the Rrm1 gene lies at 11p15.5, a tumor suppressor region, and RRM1 expression in cancer has been shown to predict responses to chemotherapy. Nevertheless, whether RRM1 is essential in mammalian cells and what the effects of its haploinsufficiency are remain unknown. To model RNR function in mice we used a mutation previously described in Saccharomyces cerevisiae (Rnr1-W688G) which, despite being viable, leads to increased interaction of the RNR complex with its allosteric inhibitor Sml1. In contrast to yeast, homozygous mutant mice carrying the Rrm1 mutation (Rrm1WG/WG) are not viable, even at the earliest embryonic stages. Proteomic analyses failed to identify proteins that specifically bind to the mutant RRM1 but revealed that, in mammals, the mutation prevents RRM1 binding to RRM2. Despite the impact of the mutation, Rrm1WG/+ mice and cells presented no obvious phenotype, suggesting that the RRM1 protein exists in excess. Our work reveals that binding of RRM1 to RRM2 is essential for mammalian cells and provides the first loss-of-function model of the RNR complex for genetic studies., This research was funded by Fundación Botín, by Banco Santander through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO; grants SAF2011-23753 and SAF2014-57791-REDC), Worldwide Cancer Research (12-0229), Fundació La Marato de TV3, Howard Hughes Medical Institute, and the European Research Council (ERC-617840) to O.F.-C., by grants from the Danish Council for Independent Research and the Danish National Research Foundation to A.J.L.-C., and by a Ph.D. fellowship from MINECO to J.S. (BES-2012-05 2030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity

  • Jacome, Ariana
  • Gutiérrez‐Martínez, Paula
  • Schiavoni, Federica
  • Tenaglia, Enrico
  • Martínez, Paula
  • Rodríguez‐Acebes, Sara
  • Lecona, Emilio
  • Murga, Matilde
  • Méndez, Juan
  • Blasco, María A.
  • Fernández-Capetillo, Óscar
The SMC5/6 complex is the least understood of SMC complexes. In yeast, smc5/6 mutants phenocopy mutations in sgs1, the BLM ortholog that is deficient in Bloom's syndrome (BS). We here show that NSMCE2 (Mms21, in Saccharomyces cerevisiae), an essential SUMO ligase of the SMC5/6 complex, suppresses cancer and aging in mice. Surprisingly, a mutation that compromises NSMCE2‐dependent SUMOylation does not have a detectable impact on murine lifespan. In contrast, NSMCE2 deletion in adult mice leads to pathologies resembling those found in patients of BS. Moreover, and whereas NSMCE2 deletion does not have a detectable impact on DNA replication, NSMCE2‐deficient cells also present the cellular hallmarks of BS such as increased recombination rates and an accumulation of micronuclei. Despite the similarities, NSMCE2 and BLM foci do not colocalize and concomitant deletion of Blm and Nsmce2 in B lymphocytes further increases recombination rates and is synthetic lethal due to severe chromosome mis‐segregation. Our work reveals that SUMO‐ and BLM‐independent activities of NSMCE2 limit recombination and facilitate segregation; functions of the SMC5/6 complex that are necessary to prevent cancer and aging in mice., The authors want to thank Jordi Torres and Mark O'Driscoll for comments on the manuscript. Work in OF laboratory related to this project was supported by Fundación Botín, by Banco Santander through its Santander Universities Global Division and by grants from MINECO (SAF2011‐23753 and SAF2014‐57791‐REDC), Howard Hughes Medical Institute, and the European Research Council (ERC‐617840). Work in JM laboratory was funded by a grant from MINECO (BFU2013‐49153P)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

USP7 is a SUMO deubiquitinase essential for DNA replication

  • Lecona, Emilio
  • Rodríguez-Acebes, Sara
  • Specks, Julia
  • López-Contreras, Andrés J.
  • Ruppen, Isabel
  • Murga, Matilde
  • Muñoz, Javier
  • Méndez, Juan
  • Fernández-Capetillo, Óscar
Post-translational modification of proteins by ubiquitin (Ub) and Ub-like modifiers regulates DNA replication. We have previously shown that chromatin around replisomes is rich in SUMO and poor in Ub, whereas mature chromatin exhibits an opposite pattern. How this SUMO-rich, Ub-poor environment is maintained at sites of DNA replication in mammalian cells remains unexplored. Here we identify USP7 as a replisome-enriched SUMO deubiquitinase that is essential for DNA replication. By acting on SUMO and SUMOylated proteins, USP7 counteracts their ubiquitination. Inhibition or genetic deletion of USP7 leads to the accumulation of Ub on SUMOylated proteins, which are displaced away from replisomes. Our findings provide a model explaining the differential accumulation of SUMO and Ub at replication forks and identify an essential role of USP7 in DNA replication that should be considered in the development of USP7 inhibitors as anticancer agents., Research was funded by Fundación Botín, Banco Santander, through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2011-23753 and SAF2014-57791-REDC), Worldwide Cancer Research (12-0229), Fundació La Marato de TV3, the Howard Hughes Medical Institute and the European Research Council (ERC-617840) to O.F.-C.; by a Marie-Curie International Outgoing Fellowship (project no. 235705) from the Seventh Framework Programme for Research and Technological Development, Marie Curie Actions, and a grant from MINECO (BFU2014-55168-JIN) that was cofunded by European Regional Development Funds (FEDER) to E.L.; by grants from the Danish Council for Independent Research and the Danish National Research Foundation to A.J.L.-C.; and by a PhD fellowship from MINECO (BES-2012-05 2030) to J.S. We would like to thank W. Gu (Columbia University) for providing Usp7lox/lox MEFs, J. Chen (MD Anderson Cancer Center) for providing Rad18-deficient HCT116 cells and J. Alegre-Cebollada (Spanish National Center for Cardiovascular Research) for help in the use of PyMOL software., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ERF deletion rescues RAS deficiency in mouse embryonic stem cells

  • Mayor-Ruiz, Cristina
  • Olbrich, Teresa
  • Drosten, Matthias
  • Lecona, Emilio
  • Vega-Sendino, Maria
  • Ortega, Sagrario
  • Domínguez, Orlando
  • Barbacid, Mariano
  • Ruiz, Sergio
  • Fernández-Capetillo, Óscar
MEK inhibition in combination with a glycogen synthase kinase-3β (GSK3β) inhibitor, referred as the 2i condition, favors pluripotency in embryonic stem cells (ESCs). However, the mechanisms by which the 2i condition limits ESC differentiation and whether RAS proteins are involved in this phenomenon remain poorly understood. Here we show that RAS nullyzygosity reduces the growth of mouse ESCs (mESCs) and prohibits their differentiation. Upon RAS deficiency or MEK inhibition, ERF (E twenty-six 2 [Ets2]-repressive factor), a transcriptional repressor from the ETS domain family, translocates to the nucleus, where it binds to the enhancers of pluripotency factors and key RAS targets. Remarkably, deletion of Erf rescues the proliferative defects of RAS-devoid mESCs and restores their capacity to differentiate. Furthermore, we show that Erf loss enables the development of RAS nullyzygous teratomas. In summary, this work reveals an essential role for RAS proteins in pluripotency and identifies ERF as a key mediator of the response to RAS/MEK/ERK inhibition in mESCs., C.M.-R. was funded by a PhD fellowship from La Caixa Foundation, T.O. was funded by a PhD fellowship from the Boehringer Ingelheim Fonds, and S.R. was funded by a Ramon y Cajal contract (RYC-2011-09242). Research was funded by Fundación Botín and Banco Santander through its Santander Universities Global Division; grants from the Spanish Ministry of Economy and Competitiveness (SAF2011-23753 and SAF2014- 57791-REDC; these projects were cofinanced with European Fonds Européen de Développement Économique et Régional [FEDER] funds), Fundació La Marato de TV3, Howard Hughes Medical Institute, and the European Research Council (ERC- 617840) to O.F.-C.; and grants from the Spanish Ministry of Economy and Competitiveness (SAF2013-49147-P and SAF2016-80874-P; these projects were cofinanced with European FEDER funds) to S.R., Peer reviewed